Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Cyclerion Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Cyclerion Therapeutics, Inc.

CYCN

Cyclerion Therapeutics, Inc.

About Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics focuses on developing novel therapeutics for neuropsychiatric and serious diseases, primarily targeting treatment-resistant depression (TRD). The company leverages its legacy soluble guanylate cyclase (sGC) assets through licensing and out-licensing agreements, aiming to generate revenue for pipeline development. It emphasizes intellectual property protection, regulatory compliance, and strategic partnerships to advance innovative treatments in high unmet medical needs.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Cyclerion Therapeutics, Inc.

1
1
Cyclerion Therapeutics, Inc. Cyclerion Therapeutics Reports $3.2 Million Net Loss in Q1 2026, Plans Merger with Korsana Biosciences

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Cyclerion Therapeutics, Inc. Cyclerion Therapeutics Reports $3.5 Million Net Loss and $2.1 Million Revenue for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Cyclerion Therapeutics, Inc. Cyclerion Therapeutics Reports Q3 2025 Revenue Growth to $875,000 Amid Increased Expenses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Cyclerion Therapeutics, Inc. Cyclerion Therapeutics Reports $93,000 Revenue in Q2 2025, Net Loss Improves

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Cyclerion Therapeutics, Inc. Cyclerion Therapeutics Reports $81,000 Revenue in Q1 2025, Focuses on TRD Development

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Cyclerion Therapeutics, Inc. Cyclerion Therapeutics Reports $2 Million Revenue and Strategic Shift Towards Treatment-Resistant Depression

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Cyclerion Therapeutics, Inc. Cyclerion Therapeutics Reports Mixed Financial Results, Significant Cash Decline, and Ongoing Concerns Over Going Concern

Via official filing (AI summary) | over 1 year ago | 0 comments